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AACAP OFFICIAL ACTIONPractice Parameter for the Assessment and
Treatment of Children and Adolescents With
Obsessive-Compulsive Disorder
Research in etiology, neurobiology, genetics, clinical correlates, and evidence-based treatments
in children and adolescents with obsessive-compulsive disorder indicate a need for the
revision of the Practice Parameters for the Assessment and Treatment of Children and
Adolescents with Obsessive-Compulsive Disorder first published a decade ago. The present
article highlights the clinical assessment and reviews and summarizes the evidence base for
treatment. Based on this evidence, specific recommendations are provided for assessment,
cognitive behavioral therapy, pharmacotherapy, combined treatment, and other interventions.
J. Am. Acad. Child Adolesc. Psychiatry, 2012;51(1):98–113. Key Words: Practice Parameter,
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eO bsessive-compulsive disorder (OCD) isa common psychiatric disorder affectingchildren and adolescents and causing
significant disability. In the previous decade
since the Practice Parameters for the Assessment
and Treatment of Children and Adolescents with
Obsessive-Compulsive Disorder were pub-
lished,1 knowledge of pediatric OCD has in-
creased with large family-genetic studies; the
elaboration of phenotypic dimensions; descrip-
tions of comorbid disorders and their moderating
effects on treatment response and outcome; re-
search on immune-based neuropsychiatric causes
(Pediatric Autoimmune Neuropsychiatric Disor-
ders Associated with Streptococcus [PANDAS]);
the publication of randomized controlled trials of
selective serotonin reuptake inhibitors (SSRIs) and
concern and scrutiny on the safety of these SSRIs in
children; the first large-scale randomized con-
trolled trials of cognitive-behavioral therapy
(CBT); new approaches in behavior therapy in-
cluding intensive in- and outpatient treatment,
family-based treatment, group therapy, and be-
havioral intervention for very young children
with OCD; and emerging data on the moderators
and predictors of response to specific treatments.
This revision of the Practice Parameters is in-
tended to incorporate recent research and empir-
ical clinical wisdom to guide child and adoles-
JOURN
98 www.jaacap.orgent psychiatrists who treat children with OCD
nd the other medical and mental health provid-
rs involved in their care.
METHODOLOGY
Information and recommendations used in this
Parameter were obtained from literature searches
using the Medline, PubMed, PsycINFO, and Co-
chrane Library databases and by an iterative
bibliographic exploration of articles and reviews,
beginning with more inclusive and sensitive
searches employing the search term “obsessive-
compulsive disorder”, multiple free text and rel-
evant medical subject headings (MeSH terms),
and an initial period from 1980 to the present day
(749 citations). The search was narrowed using
delimiters and filters such as age 0 to 18 years,
English language only, human studies, published
in the previous 10 years, and using the Boolean
operators ‘AND’ clinical trial ‘OR’ meta-analysis,
practice guideline, randomized controlled trial,
review, classical article to decrease the citations
to 322. Using similar strategies, obsessive-
compulsive disorder AND randomized con-
trolled trial were searched to yield 353 ci-
tations, including 11 reviews. Key quality
domains were examined including descriptions
of the study population (inclusion and exclusion
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AACAP OFFICIAL ACTIONcriteria), randomization, blinding, interventions,
outcomes (including “last observation carried for-
ward” data and description of dropouts), sources
of sponsorship or funding, and statistical analysis.
For this Practice Parameter, 65 publications were
selected for careful examination based on their
weight in the hierarchy of evidence attending to
the quality of individual studies, relevance to
clinical practice, and the strength of the entire
body of evidence.
EPIDEMIOLOGY
The high prevalence of OCD in children was not
generally recognized until the first epidemiologic
study just over 20 years ago.2 In that study, most
subjects identified through screening who were
later diagnosed with OCD had been previously
undiagnosed, leading to the notion of pediatric
OCD as a “hidden epidemic.” The secretive na-
ture of OCD symptoms and the isolated and
idiosyncratic functional deficits that may be se-
vere but variable and domain specific contribute
to the finding that OCD was under-recognized
and underdiagnosed in youth. Early epidemio-
logic studies were conducted in adolescent pop-
ulations and most used school surveys for sam-
ple ascertainment. The prevalence rates of
pediatric OCD are around 1% to 2% in the United
States and elsewhere.2,3 In the more recent British
Child Mental Health Survey of more than 10,000
5- to 15-year-olds, the point prevalence was
0.25% and almost 90% of cases identified had
been undetected and untreated.4 There appears
to be two peaks of incidence for OCD across the
life span, one occurring in preadolescent chil-
dren5 and a later peak in young adult life (mean
age, 21 years). If all pediatric cases of OCD
persisted in adulthood, one would expect an
increasing cumulative prevalence of OCD across
the life span as more cases are added to the
population. Studies have shown that this antici-
pated cumulative increase in prevalence is mod-
ified by the variable outcome of childhood-onset
OCD, with a substantial number becoming sub-
clinical over time.6
ETIOLOGY
Genetic Factors
The contribution of genetic factors to the devel-
opment of OCD has been explored in twin,
family-genetic, and segregation analysis stud-
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ance rates for monozygotic twins are signifi-
antly higher than for dizygotic twins. Although
amily studies also have consistently demon-
trated that OCD is familial,7 the morbid risk of
CD in first-degree relatives appears to be
reater for index cases ascertained in childhood.
or example, in their multisite family study of
dult OCD probands, Nestadt et al.10 found a risk
for OCD of almost 12% in first-degree relatives,
whereas relatives of pediatric OCD probands
showed age-corrected morbid risks from 24% to
26% in more recent studies.11 Genetic linkage
tudies of OCD have found evidence for suscep-
ibility loci on chromosomes 1q, 3q, 6q, 7p, 9p,
0p, and 15q.9 There is increasing evidence that
lutamate receptor/modulating genes may be
ssociated with OCD.12
Nongenetic Factors
Although these studies have emphasized genetic
factors, they also have pointed clearly to the
major effects of “nongenetic” influences on the
expression of OCD. For example, twin studies
have shown that, even among monozygotic
twins, OCD is not fully concordant. Clearly then,
nonheritable etiologic factors are as great or
greater than genetic factors for the risk of devel-
oping OCD. In fact, many, if not most, cases of
OCD arise without a known positive family
history of the disorder, the so-called sporadic
cases. Information on the environmental triggers
of the disorder may be especially relevant for the
sporadic form because in such cases the OCD
cannot be explained by the presence of an af-
fected relative. To date, studies have focused on
the perinatal (intrauterine [including potential
teratogens such as alcohol and tobacco], birth,
and postnatal) experiences of affected subjects13
and immune-mediated neuropsychiatric models
of illness.
Perhaps no issue has been as controversial in
OCD as that of PANDAS. The central hypothesis
of PANDAS derives from the observations of
neurobehavioral disturbance accompanying
Sydenham chorea, a sequel of rheumatic fever.
An immune response to group A -hemolytic
streptococcus (GABHS) infections purportedly
leads to cross reactivity with, and inflammation
of, basal ganglia, with a distinct neurobehavioral
syndrome that includes OCD, tics, and perhaps
hyperactivity. The diagnostic criteria were laid
out by Swedo et al.,14 but detractors have argued
99www.jaacap.org
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AACAP OFFICIAL ACTIONthat GABHS may be but one of many nonspecific
physiologic stressors that can trigger an increase
in tics or OCD.15,16[ct] At this time, the epidemi-
ologic evidence and expert clinical experience
support the belief that a small subset of children
with OCD and Tourette’s disorder have onsets
and clinical exacerbations linked to GABHS.17,18
CLINICAL PRESENTATION
Phenotype
Despite continuity in the phenotypic presenta-
tion of children and adults, issues such as limited
insight and the evolution of symptom profiles
that follow developmental themes over time may
differentiate children from adults with OCD.19
Symptoms of OCD are frequently hidden or
poorly articulated, especially in younger chil-
dren. In addition, children with OCD may dis-
play compulsions without well-defined obses-
sions and rituals other than the typical washing
or checking (e.g., blinking and breathing ritu-
als).20 Most children exhibit multiple obsessions
and compulsions (mean numbers over the life-
time have been reported as 4.0 and 4.8, respec-
tively).20 Neither gender nor age at onset has
been reported to determine the type, number, or
severity of OCD symptoms. Children’s obses-
sions often center on a fear of a catastrophic
family event (e.g., death of a parent). Contami-
nation, sexual, and somatic obsessions, and ex-
cessive scruples/guilt are the most commonly
reported obsessions, and washing, repeating,
checking, and ordering are the most commonly
reported compulsions.19 OCD symptoms tend to
wax and wane and are persistent in most patients,
changing over time so that the presenting symptom
constellation is not maintained.20 Efforts have been
made to parse the heterogeneous symptoms of
OCD into a few consistent and temporally stable
symptom dimensions using factor or cluster ana-
lytic methods. The Dimensional Yale-Brown
Obsessive-Compulsive Scale21 measures the pres-
ence and severity of OC symptoms within several
distinct dimensions that combine thematically re-
lated obsessions and compulsions.
Early-onset cases have a high frequency of
subjective sensations known as “sensory phe-
nomena” preceding or accompanying their com-
pulsions. Physical sensations include localized
tactile and musculoskeletal sensations, and men-
tal sensations include “just-right” perceptions (to
tactile, visual, and auditory sensory stimuli) and
“incompleteness” (or need for accuracy).22
JOURN
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to-female ratio, with more boys at younger ages.
The mean age of onset of pediatric OCD ranges
from 7.5 to 12.5 years (mean, 10.3  2.5 years)
nd the mean age at ascertainment ranges from
2 to 15.2 years (mean, 13.2 years),5 documenting
that, on average, the age at assessment was 2.5
years after the age at onset, a finding of consid-
erable clinical importance. Pediatric-onset OCD
is increasingly recognized as a putative develop-
mental subtype of the disorder, based on in-
creased familial aggregation, psychiatric comor-
bidity, and outcome data.11
Psychiatric Comorbidity
OCD in youth is usually accompanied by another
psychopathology that may complicate the assess-
ment and treatment of affected children. Even
cases derived from epidemiologic studies, which
avoid the referral bias inherent in many clinical
studies, have demonstrated rates of comorbid
psychiatric diagnoses in more than 50% of af-
fected children.2 Irrespective of current age, a
younger age at the onset of OCD predicts in-
creased risks for comorbid attention-deficit/
hyperactivity disorder (ADHD), separation anxiety
disorder, specific phobias, agoraphobia, and mul-
tiple anxiety disorders. Mood and psychotic dis-
orders are associated with increasing chronologic
age. Tourette’s disorder has shown associations
with age at onset (tics are more frequent in
younger patients), gender (tics are more preva-
lent in boys), and chronologic age (tics usually
improve or remit in the second decade of life).23
Neuropsychological Findings
Although not part of the core diagnostic symp-
toms, interest in a neuropsychological “endophe-
notype” in children with OCD has grown during
recent years out of clinical and anecdotal experi-
ences that many children have academic difficul-
ties that are not wholly explained by their pri-
mary disorder. Given the potential involvement
of frontostriatal systems in OCD, several aspects
of neuropsychological performance have been
especially relevant, including measurements of
visuospatial integration, processing speed, short-
term memory, attention, and executive function.
Although not yet well characterized, deficits in
visual spatial performance and processing speed
appear common.24
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AACAP OFFICIAL ACTIONCLINICAL COURSE AND OUTCOME
Precipitating psychosocial stressors have been
described in several reports indicating that these
are occasionally associated with the onset of
OCD, sometimes dramatically.25 However, most
pediatric non-PANDAS OCD cases do not pro-
vide a history of clear precipitating triggers and
has a subclinical onset. The long-term prognosis
for pediatric OCD is better than originally con-
ceived. Many children will remit entirely or
become clinically subthreshold over time.5 A
younger age of OCD onset, an increased duration
of OCD, inpatient treatment, and perhaps spe-
cific symptom subtypes, such as sexual, religious,
or hoarding obsessions, predict greater persis-
tence. Comorbid psychiatric illness and poor
initial treatment response are adverse prognostic
factors. In contrast, gender, age at assessment,
and length of follow-up are not reported as
predictors of remission or persistence. Psychoso-
cial function is frequently compromised. Studies
have reported high levels of social/peer prob-
lems (55–100%), isolation, unemployment (45%),
and difficulties sustaining a job (20%). However,
at follow-up in one study, pediatric subjects with
OCD showed no difference from controls in
educational achievement, with 30% to 70% hav-
ing attended college.5
DIFFERENTIAL DIAGNOSES
Normal Development
Toddlers and preschoolers frequently engage in
ritualistic behavior as a part of normal develop-
ment. Examples include mealtime or bedtime
routines that are insisted on. As a rule, they do
not cause impairment in family functioning and
an interruption of the rituals does not create
severe distress in the child.
Other Psychiatric Disorders
Perhaps the most difficult differential diagnosis
occurs in the context of a more pervasive devel-
opmental disorder (PDD or “spectrum” disor-
der). Core symptoms of these disorders include
stereotypic and repetitive behaviors, a restricted
and narrow range of interests, and activities that
may be confused with OCD, especially in young
children. A small number of children with OCD
(5%) may also meet criteria for Asperger’s
disorder or PDD.23 In addition to the core social
and communication deficits that are a diagnostic p
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ul criterion for clinicians to differentiate PDD
rom OCD is whether symptoms are ego-
ystonic and are associated with anxiety-driven
bsessional fears. Children with PDD frequently
ngage in stereotypic behaviors with apparent
ratification and will become upset only when
heir preferred activities are interrupted. Another
elpful factor is whether symptoms are typical
f OCD (such as washing, cleaning, or checking)
rom which one can infer some obsessional
oncern.
Another diagnostic dilemma occurs in the
ontext of the poor insight of obsessional
houghts, which merge into overvalued ideas
nd even delusional thinking suggesting psycho-
is. In fact, insight in children with OCD is not
tatic but varies with anxiety levels and is best
ssessed when anxiety is at a minimum. Al-
hough OC symptoms may rarely herald a psy-
hotic or schizophreniform disorder in youth,
specially in adolescents, other positive or nega-
ive symptoms of psychosis will usually be pres-
nt or emerge to assist in the differential diagno-
is, and the nature of obsessional ideation in
hese patients is often atypical.
Although the diagnosis of obsessive-compulsive
ersonality disorder (OCPD) is rarely used
ith young children, OCPD features (defined as
pervasive pattern of preoccupation with order-
iness, perfectionism, and control at the expense
f flexibility and efficiency, beginning by early
dulthood) are sometimes present and docu-
ented on Axis II in adolescent evaluations.
ome children also demonstrate a preoccupation
ith minute details and facts, follow rules and
egulations rigidly, adhere strongly to routines
nd schedules, and are inflexible, even relentless,
n their thoughts or in pursuing their wishes.
lthough these behaviors are typically ego-
yntonic and insight is lacking, these children do
ot meet the diagnostic criteria for Asperger’s
isorder because they do not have core deficits of
mpathy and social pragmatic skills. Such chil-
ren may be critical or judgmental toward oth-
rs, or angry and even aggressive when events
o not conform to expectations or wishes, lead-
ng to significant family disruption. Only longi-
udinal studies can show if these children de-
elop OCPD later. Serotonergic medications are
f limited help for such children and treatment is
rimarily behavioral.
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PRACTICE PARAMETERS
In this Parameter, recommendations for best as-
sessment and treatment practices are stated in
accordance with the strength of the underlying
empirical and/or clinical support, as follows:
• Clinical standard [CS] is applied to recommen-
dations that are based on rigorous empirical
evidence (e.g., meta-analyses, systematic re-
views, individual randomized controlled tri-
als) and/or overwhelming clinical consensus.
• Clinical guideline [CG] is applied to recom-
mendations that are based on strong empirical
evidence (e.g., nonrandomized controlled tri-
als, cohort studies, case-control studies) and/
or strong clinical consensus.
• Option [OP] is applied to recommendations
that are based on emerging empirical evidence
(e.g., uncontrolled trials or case series/reports)
or clinical opinion but lack strong empirical
evidence and/or strong clinical consensus.
• Not endorsed [NE] is applied to practices that
are known to be ineffective or contraindicated.
The strength of the empirical evidence is rated in
descending order, as follows:
• Randomized controlled trial (rct) is applied to
studies in which subjects are randomly as-
signed to two or more treatment conditions.
• Controlled trial (ct) is applied to studies in
which subjects are nonrandomly assigned to
two or more treatment conditions.
• Uncontrolled trial (ut) is applied to studies in
which subjects are assigned to one treatment
condition.
• Case series/report (cs) is applied to a case
series or a case report.
RECOMMENDATIONS
Recommendation 1. The psychiatric assess-
ment of children and adolescents should rou-
tinely screen for the presence of obsessions
and/or compulsions or repetitive behaviors.
[CG]
Clinicians should screen for OCD even when it
is not part of the presenting complaint. Symp-
toms may be of mild to moderate severity, wax
and wane over time, be prominent in one setting
and not another, and be kept secret from others
(including family). The simplest probes are those
that derive from the diagnostic criteria of the
DSM-IV: “Do you ever have repetitive, intrusive
or unwanted thoughts, ideas, images or urges
JOURN
102 www.jaacap.orgthat upset you or make you anxious and that you
cannot suppress?” For younger children the
question might be phrased, “Do you have wor-
ries that just won’t go away?” It is reasonable to
offer some examples at this time such as “worries
about things not being clean” or “worrying that
something bad might happen to you or someone
you love.”
For compulsions, a similar probe might be:
“Do you ever have to do things over and over,
even though you don’t want to or you know they
don’t make sense, because you feel anxious or
worried about something?” For younger chil-
dren, the question might be phrased, “Do you do
things over and over or have habits you can’t
stop?” Examples such as washing, checking, re-
peating, ordering, counting, and hoarding can be
offered easily and quickly.
Sometimes adults are left to infer obsessions
that are not articulated or even acknowledged by
observing behaviors in their children. Examples
include avoidance behaviors that imply concerns
about some normal and expected activity such as
entering a room or handling an object. If screen-
ing questions suggest that OC symptoms are
present, clinicians should follow with more in-
depth assessment. The commonly employed
parent-report Child Behavior Checklist26 includes 8
items derived from factor analysis shown to have
good sensitivity and specificity as a screen for
OCD in children,27 although even simple positive
tem scores using item 9 (“obsessions”), item 66
“compulsions”), and item 112 (“worries”) ap-
ear equally useful. The message for clinicians is
hat screening for OCD is straightforward and
hat simple probes will reveal the great majority
f cases.
ecommendation 2. If screening suggests OC
ymptoms may be present, clinicians should
ully evaluate the child using the DSM-IV-TR
riteria and scalar assessment. [CS]
The diagnostic criteria of time occupied by
C symptoms, the level of subjective distress,
nd functional impairment, in addition to a
tandardized inventory of symptoms and a
calar assessment of severity are best captured
y a reliable instrument such as the Children’s
ale-Brown Obsessive Compulsive Scale (CY-
OCS).28 The CY-BOCS is a 10-item anchored
ordinal scale (0–4) that rates the clinical sever-
ity of the disorder by scoring the time occu-
pied, the degree of life interference, subjective
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AACAP OFFICIAL ACTIONdistress, internal resistance, and degree of con-
trol for obsessions and compulsions. It has
been validated for use with pediatric subjects.28
The CY-BOCS also includes a symptom check-
list of more than 60 symptoms of obsessions
and compulsions categorized by the predomi-
nant theme involved, such as contamination,
hoarding, washing, checking, etc. Scores of 8 to
15 represent mild illness, 16 to 23 moderate
illness, and at least 24 severe illness. Equally
important are quantitative measurements of
avoidance, insight, indecisiveness, “pathologic”
responsibility, doubt, and obsessional “slow-
ness.” The CY-BOCS is a clinician-administered
instrument that is most informative when given
to children and their parents, where a “worst-
report” algorithm is likely to be most accurate.
Although the CY-BOCS is the current stan-
dard assessment tool for pediatric OCD, there
are several important limitations to this scale.
The first is that the avoidance rating is not
included in the quantitative score of the scale,
which may therefore underestimate severity
when avoidance is a large part of the present-
ing behavior. Second, the scale is not linear.
Three to 8 hours of obsessions or compulsions
rates an ordinal score of 3, whereas longer than
8 hours scores a 4 (the maximum) on the scale.
It is for this reason that a 25% to 40% decrease
in the CY-BOCS scale score is considered a
clinically significant response. Third, the heter-
ogeneous nature of OCD is such that atypical
symptoms may not be captured by the CY-
BOCS symptom checklist. Examples include
behaviors driven by sensory discomfort or a
fear of a “transformation” into other people or
of acquiring an unwanted character trait from
another (an uncommon form of contamina-
tion). The mean CY-BOCS score at the ascer-
tainment of OCD in children and adolescents in
several studies was 23 (standard deviation,
6.5), indicating moderate to severe illness.5
Other OCD scales, such as the Leyton Obses-
sional Inventory,29 and interviews that assess
more broadly for internalizing symptoms (Ten
Year Review of Rating Scales II: Scales for Inter-
nalizing Disorders)30 and anxiety, such as the
Anxiety Disorders Interview Schedule for Chil-
dren,31 the Pediatric Anxiety Rating Scale,32 the
Screen for Child Anxiety Related Disorders,33
and the Multidimensional Anxiety Scale for Chil-
dren,34 may also be helpful. m
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evaluation should be performed, including
information from all available sources and
comprising standard elements of history and
a mental state examination, with attention to
the presence of commonly occurring comor-
bid psychiatric disorders. [CS]
Psychiatric comorbidity is the rule in youth with
OCD, seen in clinically referred and epidemiologic
samples and specialty and nonspecialty child psy-
chiatry settings.35 Storch et al.36[ut] found that 74%
f youth with OCD met the criteria for at least one
omorbid diagnosis, and those children with at
east one comorbid diagnosis had a lower treat-
ent response and remission rates with CBT com-
ared with those without a comorbid diagnosis.
he presence of disruptive behavior disorders in
articular may represent a therapeutic challenge
or clinicians. The identification ofmajor depressive
isorder and bipolar disorder is especially impor-
ant before the initiation of an SSRI. Because certain
omorbid disorders may adversely moderate the
utcome of CBT and the medication treatment of
ediatric OCD, careful assessment and treatment of
ther psychiatric disorders before and concurrent
ith the treatment of OCD may improve the final
utcome in subjects with OCD at all ages (see
ecommendation 8).
Comorbid eating disorders are infrequent in
readolescent children with OCD but become
ore prevalent during adolescence.35,37 In these
hildren, medical considerations outweigh other
oncerns of psychopathology (except suicidality)
nd must be addressed and stabilized to permit
ental health interventions. A “spectrum” of com-
ulsive/impulsive habit disorders such as tricho-
illomania, compulsive nail biting, skin picking,
nd other forms of self-injury shares important
eatures with OCD but also has important differ-
nces. Although stress may exacerbate these symp-
oms, they are usually not preceded by specific
ognitions (obsessions), but rather a sense of ten-
ion that is general or localized. The impulsive
ehaviors are frequently a source of (temporary)
ratification but may be followed by remorse and
hame. Behavioral therapy is the mainstay of treat-
ents for these disorders because standard SSRI
edications are often less helpful. Body dysmor-
hic disorder usually onsets in adolescence when
ormal developmental pressures increase the focus
n appearance and attraction among peers, but it
ay also begin in childhood.
103www.jaacap.org
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AACAP OFFICIAL ACTIONRecommendation 4. A full medical, develop-
mental, family, and school history should
be included with the psychiatric history and
examination. [CG]
Family Accommodation. Children are embedded
in families and, not surprisingly, families may
become deeply enmeshed in their children’s OCD.
Parental efforts to relieve a child’s anxiety may
inadvertently lead to an accommodation and rein-
forcement of OC behaviors such as providing ver-
bal reassurance or other “assistance” to children,
for example, handling objects that children avoid
such as opening doors, laundering “contaminated”
clothes and linens, and evenwiping children on the
toilet who will not do it themselves. The very high
intensity of affect and irritability displayed by some
affected children engaged in ritualistic behaviors
makes it difficult for parents to react with the
supportive yet detached responses needed for ef-
fective behavioral management. The role of indi-
vidual family members in the maintenance and
management of OC symptoms is important to
assess. The familial nature of anxiety disorders and
OCD is an added factor in families’ responses to a
child with OCD. Detailed and specific questions
about activities of daily living may be needed to
understand the cycle of OC behaviors at home.
Medical History. Medical inquiry should focus on
the CNS during a systems review with attention to
trauma and neurologic symptoms (e.g., choreiform
movements). Recently, attention to infection with
GABHS as a potential precipitant for a PANDAS-
associated OCD14[ct] has increased. Inquiry of an
infection with GABHS is indicated in acute and
dramatic onsets or exacerbations in preadolescent
patients or when a child in remission suddenly
relapses. Neurologic signs, such as chorea, are
evidence of rheumatic fever but may not occur for
many months after infection. “Soft” neurologic
signs, such as tremor and coordination difficulties
on examination, are one criterion of the PANDAS
diagnosis.14,17 Antistreptococcic antibodies such as
antistreptolysin O and anti-DNase B are present in
most children by early adolescence, but a 0.2 log
increase (doubling) in titers is considered evidence
of a recent infection. Intercurrent titers may be
helpful because exacerbations can be assayed with
subsequent titers to detect any sudden increase in
antibody levels, but a GABHS culture is the inves-
tigation of choice. Positive antistreptococcic anti-
body titers are not, by themselves, an indication for
antibiotic treatment. At the present time, no neuro-
imaging procedures have been validated for the c
JOURN
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bid disorders.
Educational Assessment. School and educational
histories provide an ecologically valid and impor-
tant measurement of function and of illness sever-
ity. OC symptoms that spill into the school setting
imply more anxiety, stronger compulsions, less
insight, and less resistance and control. Therefore,
educational impairment denoted by falling grades,
the need for extra help, or special class placement
indicate more urgency for treatment and could
justify more aggressive interventions, including
medications. Beyond this, there is increasing inter-
est in a specific neuropsychological pattern of dys-
function that may be characteristic of pediatric
OCD, evidenced by impairments in visual mem-
ory, visual organization, and processing speed.
Children with evidence of this pattern often are
dysgraphic, prefer reading to writing, and have
stronger language than math skills. Impairments in
planning complicate the generalization of CBT
skills to new situations. A consideration for neuro-
psychological assessment, intelligence, and aca-
demic achievement testing should be high in chil-
dren with OCD who are struggling at school,
especially if the difficulties are chronic and not
specifically associated with OCD.
Recommendation 5. When possible, CBT is the
first line treatment for mild to moderate cases of
OCD in children. [CS]
Perhaps the greatest progress in the previous
decade pertains to well-conducted systematic trials
of CBT applied to children with OCD. Since the
publication of a CBT treatment manual that opera-
tionalized and systematized this method,38 numer-
us studies have consistently shown its acceptabil-
ty and efficacy.39 “Unlike other psychotherapies
hat have been applied, usually unsuccessfully, to
CD, cognitive behavioral treatment presents a
ogically consistent and compelling relationship
etween the disorder, the treatment, and the spec-
fied outcome.”38 However, a recent survey of
clinicians involved in the treatment of pediatric
OCD found that only one third regularly used
exposure techniques, one third “sometimes” used
them, and the remaining third reported “rarely or
never using” them. The protocol used by March et
al. in the National Institute of Mental Health Pedi-
atric Obsessive-Compulsive Disorder Treatment
Study (POTS)40[rct] consists of 14 visits over 12
eeks spread across five phases: psychoeducation,
ognitive training, mapping OCD, exposure and
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AACAP OFFICIAL ACTIONresponse prevention (E/RP), and relapse preven-
tion and generalization training. Except for weeks 1
and 2, when patients come twice weekly, all visits
are administered once per week, last 1 hour, and
include one between-visit 10-minute telephone
contact scheduled during weeks 3 through 12. Each
session includes a statement of goals, a review of
the preceding week, a provision of new informa-
tion, therapist-assisted practice, homework for the
coming week, and monitoring procedures. Not
infrequently, several limitations may preclude de-
livery of CBT as a first-line treatment option, as
discussed inmore detail under Recommendation 6.
Exposure and response prevention (E/RP) relies
on the fact that anxiety usually attenuates after a
sufficient duration of contact with a feared stimu-
lus.41 Repeated exposure is associated with a de-
creased anxiety across exposure trials, with the
decrease in anxiety largely specific to the domain of
exposure, until the child no longer fears contact
with specifically targeted phobic stimuli.42[ut] Ade-
quate exposure depends on blocking the negative
reinforcement effect of rituals or avoidance behav-
ior, a process termed “response prevention”. For
example, a child with germ worries must not only
touch “germy things” but also refrain from ritual-
ized washing until his or her anxiety diminishes
substantially. E/RP is typically implemented in a
gradual fashion (sometimes termed “graded expo-
sure”), with exposure targets under a patient’s or,
less desirably, a therapist’s control. Different cog-
nitive interventions have been used to provide the
child with a “tool kit” to facilitate compliance with
E/RP. The goals of cognitive therapy typically
include increasing a sense of personal efficacy,
predictability, controllability, and self-attributed
likelihood of a positive outcomewithin E/RP tasks.
Each must be individualized and must mesh with
the child’s cognitive abilities and developmental
stage. Modeling, whether overt (the child under-
stands that the therapist is demonstrating more
appropriate or adaptive coping behaviors) or co-
vert (the therapist informally models a behavior),
may help improve compliance with in-session
E/RP and generalization to between-session E/RP
homework. Modeling may decrease anticipatory
anxiety and provide an opportunity for practicing
constructive self-talk before and during E/RP.
Clinically, positive reinforcement (rewards) seems
not to directly alter OCD symptoms, but rather
helps to encourage exposure and so produces a
noticeable, if indirect, clinical benefit. In contrast,
punishment is unhelpful in the treatment of OCD.
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ent for E/RP and proscribe contingency manage-
ent procedures unless targeting disruptive be-
avior outside the domain of OCD.
Excellent CBT manuals and self-help books are
vailable for therapists and families interested in
eveloping mastery of these techniques, such as
alking Back to OCD: The Program that Helps Kids and
eens Say “No Way” and Parents Say “Way to Go” by
ohnMarch, M.D.; Obsessive Compulsive Disorders: A
omplete Guide to Getting Well and Staying Well by
red Penzell, Ph.D.; Freeing Your Child from Obses-
ive Compulsive Disorder by Tamar Chansky, Ph.D.;
nd What to do When your Child has Obsessive Com-
ulsive Disorder: Strategies and Solutions, by Aureen
into Wagner, Ph.D. These may be found on the
CD Foundation Web site resource section at
ww.ocfoundation.org.
In a recent meta-analysis of five randomized
ontrolled trials of CBT (N  161) in children
ith OCD, Watson and Rees39 found a large
mean pooled effect size of 1.45 (95% confidence
interval [CI] 0.68–2.22), albeit with less precision
and greater heterogeneity in CBT studies com-
pared with pharmacotherapy trials. Several varia-
tions in delivering CBT have been studied and
reported including those that use family-based
approaches.43[rct] Without question, families must
e involved in the treatment of younger children
ith OCD, where parents control many contingen-
ies of their daily activity.44 Another variation
shown to be helpful is CBT delivered in group
settings,45[ut] where the positive elements of group
herapy and CBT are combined. Intensive CBT
pproaches work well for children who subscribe
n advance to this approach46[ut] and may be espe-
cially useful for treatment-resistant OCD or for
patients who desire a very rapid response.
Recommendation 6. For moderate to severe
OCD, medication is indicated in addition to
CBT. [CS]
Although CBT is the first line of treatment in
mild to moderate and, depending on the patient’s
and doctor’s preference, even severe cases of OCD,
more severe symptoms are an indication for med-
ication, preferably added to CBT. Scores higher
than 23 on the CY-BOCS or Clinical Global Impres-
sion Severity Scale of marked to severe impairment
based on time occupied, subjective distress, and
functional limitations provide a threshold for the
consideration of drug intervention. In addition, any
situation that could impede the successful delivery
105www.jaacap.org
p
t
t
S
i
p
y
o
p
a
a
i
0
s
t
a
c
t
1
e
6
e
c
c
S
i
AACAP OFFICIAL ACTIONof CBT should be cause for an earlier consideration
of medication treatment. For example, a child may
be too ill or may refuse to engage in CBT. Concur-
rent psychopathology, including multiple anxiety
disorders, major mood disturbance and disruptive
behavioral disorders, including ADHD, may de-
crease the acceptance of, or adherence to, CBT and
may require medication in its own right. For exam-
ple, a depressed adolescent with amood-congruent
anhedonic view of the future may see little point in
making the effort to tolerate E/RP, and therefore
major depression may mediate a poor response to
CBT, leaving pharmacotherapy as the best
option.36[ut] Individual and family factors also are
important considerations. Poor insight into the ir-
rational nature of the obsession and/or compulsion
can lead to resistance to CBT. The need for close
family involvement will make successful imple-
mentation of CBT more difficult in chaotic or non-
intact families. There is a dire shortage of skilled
CBT practitioners with the training to deliver the
best standard of CBT in many areas, so that com-
bined treatment or medication only may be the
default treatment of first choice, even for cases with
lower scalar scores and lesser degrees of impair-
ment. Site-specific differences in CBT outcomes in
the POTS40[rct] have suggested variability in the
outcomes for CBT and medication alone compared
with combined treatment, which is immune to said
variation. This implies that, in the absence of expert
CBT, the choice of combined treatment is also
favored because outcomes are better even in the
absence of expert CBT. In this context, informed
consent is not fully “informed” without a discus-
sion of CBT specifically and not just talk therapy,
for the simple reason that outcomeswith CBT alone
or CBT plus medication are superior to medication
alone.
Recommendation 7. SRIs are the first-line med-
ications recommended for OCD in children and
should be used according to AACAP guidelines
to monitor response, tolerability, and safety.
[CS]
Efficacy. The previous decade has seen rapid
advances in the knowledge of the pharmacother-
apy of OCD affecting children and adolescents.
Clomipramine, the first agent approved for use in
pediatric populations with OCD,47[rct] did not gain
approval from the U.S. Food and Drug Adminis-
tration (FDA) until 1989. Subsequent industry-
sponsored multisite randomized controlled tri-
als have demonstrated significant efficacy of
JOURN
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sertraline,48[rct] fluvoxamine,49[rct] fluoxetine,50[rct] and
aroxetine.51[rct] Unfortunately, no comparative
reatment studies have yet been performed and
here is little to guide clinicians in their choice of
SRIs.
The cumulative data accrued from random-
zed controlled trials of pediatric OCD over the
revious 10 years, involving more than 1,000
outh, are sufficient to examine the overall effect
f medication treatment. A meta-analysis of all
ublished randomized controlled medication tri-
ls in children and adolescents with OCD found
n effect size (expressed as a pooled standard-
zed mean difference for results of all studies) of
.46 (95% CI 0.37–0.55) and showed a statistically
ignificant difference between drug and placebo
reatments (z  9.87, p  .001).52 Differences in
bsolute response rate (defined as 25% de-
rease in CY-BOCS scores after treatment) be-
ween an SSRI and placebo have ranged from
6% (sertraline and fluvoxamine) to 24% (fluox-
tine), yielding a number needed to treat of 4 to
. However, a multivariate regression of drug
ffect controlled for other variables showed that
lomipramine (a nonselective SRI) was signifi-
antly superior to each of the SSRIs, whereas
SRIs were comparably effective.52 In the absence
of head-to-head trials, it is not clear if clomip-
ramine is truly superior to SSRIs or, as is more
likely, if the meta-analytic findings reflect the
order in which the trials were done along with
their methodologic rigor. Superior or not, clo-
mipramine is generally not used as the drug of
first choice for children because of its frequent
adverse event profile47[rct] and concerns of mon-
toring potential arrhythmogenic effects.53 Al-
though highly significant statistically, the overall
effect sizes of medication were modest. These
statistics translate into an improved CY-BOCS
score of about 6 points of drug over placebo. It is
also possible that placebo response rates in OCD
are lower than in other anxiety disorders. Since
then, the POTS40[rct] confirmed these findings,
with an effect size of 0.66 (95% CI 0.12–1.2) for
sertraline, whereas a recent meta-analysis of 10
randomized controlled trials39 showed an overall
drug effect size of 0.48 (95% CI 0.36–0.61) and a
clomipramine an effect size of 0.85 (95% CI
0.32–1.39). Although the effect size for CBT
appears larger than that for medication, meta-
analysis cannot determine which treatment is more
effective because differences in design (e.g.,
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AACAP OFFICIAL ACTIONplacebo-control versus wait-list condition) and
study population, rather than differences in effi-
cacy of interventions, could account for
differences in observed effect sizes. In the
POTS,40[rct] CBT alone did not differ statistically
from sertraline alone on scalar outcomes but was
superior for the remission rate; CBT and sertraline
were better than placebo. Long-term studies are
fewer but have suggested a cumulative benefit over
longer periods of drug exposure with gradually
decreasing scalar scores and increasing remission
rates for sertraline54[ut] up to periods of 1 year.
Safety and Tolerability. In general, SSRI medica-
tions are well-tolerated medications and safer than
their predecessor, the tricyclic antidepressants, es-
pecially in the setting of misuse or overdose. Titra-
tion schedules should be conservative, withmodest
increases from the initial dose each 3 weeks or so to
allow for an improvement to manifest before ag-
gressively increasing doses (Table 1). Patience is
key to successful outcomes because it may take 12
weeks for substantial benefits to occur. Treatment is
generally continued for 6 to 12 months after stabi-
lization (“the dose that gets you well is the dose
that keeps you well”) and then very gradually
withdrawn over several months. CBT “booster”
sessions may be helpful to address any recurrence
of symptoms during or after medication discontin-
uation and to prolong remission. Two or three
relapses of at least moderate severity should lead to
a consideration of longer-term treatment (years).
Clinicians should be aware of behavioral side
effects that are more likely in younger children55
and may be late-onset adverse effects appearing in
parallel with a decrease in anxiety. In a study by
TABLE 1 Dosing Guidelines
Drug
Starting Dose (mg)
Preadolescent
Clomipramineb,c 6.25–25
Fluoxetineb,d 2.5–10
Sertralineb,d 12.5–25
Fluvoxamineb,c 12.5–25
Paroxetinee 2.5–10
Citalopramd 2.5–10
Note: aMean daily doses used in randomized controlled trials.
bApproved by the Food and Drug Administration for obsessive-compulsive
cDoses lower than 25 mg/day may be administered by compounding 2
dOral concentrate commercially available.
eOral suspension commercially available.Martin et al.,55 peripubertal children exposed to a
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ania compared with adolescents and young
dults. For children with anxiety disorders or mild
epression, the number needed to harm (NNH)
as 13 (95% CI 11–15). These side effects are
ensitive to dose adjustment and the goal is to find
therapeutic window that provides an adequate
linical response but “acceptable” degrees of be-
avioral activation. If not achievable, then rotation
o another SSRI is indicated. Black box warnings
rom the FDA about suicide exist for all antidepres-
ant medications in the United States, but it should
e noted that no suicides occurred in any of the
ediatric randomized controlled trials of SSRIs. In
he most comprehensive analysis of the extant data
tratified by diagnosis, Bridge et al.56 found no
tatistically significant increased risk of suicidal
hinking or behavior in the pooled pediatric OCD
rials. The pooled absolute risk difference be-
ween SSRI- and placebo-treated youth with
CD was 0.5%, with an NNH of 200. In contrast
o trials of serotonin-norepinephrine reuptake
nhibitor and SSRI medications in OCD and
nxiety disorders, in which the risk of a suicidal
vent is small to negligible, the risk of a suicidal
vent is notably larger in antidepressant trials,
articularly for adolescents.
The use of clomipramine mandates an evalua-
ion of the pediatric patient’s medical condition and
ardiac status in particular. The baseline evaluation
hould include a systems review and inquiry for a
ersonal or family history of heart disease. A his-
ory of nonfebrile seizures should be noted but is
ot an absolute contraindication. A general pediat-
ic examination to include auscultation of the heart
Typical Dose Range (mg) (Mean Dose)aescent
50–200
0 10–80 (25)
0 50–200 (178)
0 50–300 (165)
10–60 (32)
0 10–60
der in children and adolescents.
into a 5-mL suspension.Adol
25
10–2
25–5
25–5
10
10–2
disor
5 mgnd measurement of pulse and blood pressures is
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AACAP OFFICIAL ACTIONindicated. A baseline (pretreatment) electrocardio-
gram should be requested. Guidelines regarding
unacceptable electrocardiographic (EKG) indices
for the use (or increase) of clomipramine have been
recommended by the FDA: a PR interval longer
than 200 ms, a QRS interval more than 30% in-
creased over baseline or longer than 120 ms, blood
pressure greater than 140 systolic or 90 diastolic
and a heart rate faster than 130 beats/min at rest.53
A prolonged QTc (450 ms) is associated with an
increased risk of ventricular tachyarrhythmias and
is a contraindication for clomipramine use (or fur-
ther increase). Adverse events are common with
clomipramine, including anticholinergic, adrener-
gic, and histaminergic effects (dry mouth, constipa-
tion, dizziness, postural hypotension, sweating,
and sedation) that occur in up to 60% of children.47
It should be noted that very limited knowl-
edge is available of what effects SSRIs have on
brain development.57
Recommendation 8. The modality of assigned
treatment should be guided by empirical evi-
dence on the moderators and predictors of treat-
ment response. [CS]
Psychiatric comorbidity may have a signifi-
cant influence on treatment response. One trial of
children and adolescents treated with an SSRI for
OCD showed that, although the response rate in
the overall treated sample was high (71%), pa-
tients with comorbid ADHD, tic disorder, or
oppositional defiant disorder had response rates
significantly lower (56%, 53%, and 39%, respec-
tively) than patients with OCD only (75%).58[rct]
Further, comorbidity was associated with a
higher rate of relapse after treatment in the total
patient population (32% for no comorbidity ver-
sus 46% for at least one comorbid disorder, p 
.04; 56% for at least two comorbid disorders, p 
.05). More recent work has confirmed these find-
ings. March et al.59 conducted a post hoc analysis
of data from the POTS40[rct] comparative treat-
ment trial and found that those with a comorbid
tic disorder failed to respond to sertraline alone
and did not differ statistically from placebo-
treated patients, whereas the response in youth
with OCD without tics replicated previously
published intent-to-treat outcomes. In children
with comorbid tics, sertraline was helpful only
when combined with CBT, whereas CBT alone
without medications remained effective. There-
fore, children with comorbid tics should be as- i
JOURN
108 www.jaacap.orgsigned to CBT or combined CBT with medication
as a first option.
In contrast, children with a positive first-
degree family history of OCD responded far less
well to CBT only compared with those without
such a history and are good candidates for initial
combined treatment.60[rct] Although the reasons
are not clear, high levels of parental accommo-
dation may inadvertently lead to treatment resis-
tance. However, it is difficult to disentangle be-
havioral factors from greater genetic loading that
may manifest as a more familial form of OCD
and more severe and treatment resistant illness.
In the comparative POTS, youth with lower
severity scale scores, less OCD-related impair-
ment, fewer comorbid externalizing symptoms,
better insight, and lower levels of family accom-
modation showed greater improvement across
treatment conditions (predictors of positive re-
sponse) and are therefore good candidates for
CBT as a first line of treatment.60[rct]
Recommendation 9. Multimodal treatment is
recommended if CBT fails to achieve a clinical
response after several months or in more severe
cases. [CS]
For greatest efficacy, the combination of CBT
and medication is the treatment of choice and
should be considered the default option for first-
line treatment in moderate to severe OCD. Rec-
ommendations from the comparative treatment
trial were to start treatment with CBT alone or
combined CBT plus medication treatment.40[rct]
Combined treatment showed the greatest de-
crease in symptom scores and remission rate,
with an effect size that was more or less the
arithmetic sum of the component treatments
(CBT  0.97, sertraline  0.67, combined  1.4).
ifty-four percent of children receiving the com-
ined treatment achieved a complete remission
defined by CY-BOCS score 10) and an unad-
usted mean decrease of at least 10 points on the
Y-BOCS. Note that this recommendation does
ot call for switching to medication treatment if
BT alone is unsuccessful, but rather the addi-
ion of medication to concurrent CBT. It is possi-
le that one of the greatest benefits of medicine is
o mediate better outcomes of CBT by decreasing
nxiety and improving a child’s ability to tolerate
/RP. Although sertraline was the medication
sed in the POTS, it is reasonable to extrapolate
he POTS findings to other medications that have
ndependently shown efficacy for OCD in chil-
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cotherapy are outlined in the POTS method arti-
cle61 and the article by Storch et al.36[ut]
Recommendation 10. Medication augmentation
strategies are reserved for treatment-resistant
cases in which impairments are deemed mod-
erate in at least one important domain of func-
tion despite adequate monotherapy. [OP]
Treatment Resistance. As a general principle,
treatment resistant refers to a patient who has not
responded to interventions known to be effective
for the specific condition being treated. Applied
to children with OCD, this indicates persistent
and substantial OCD symptomatology in the face
of adequate treatment known to be effective in
childhood OCD. Experience supports at least two
SRI trials as a necessary precondition to declare
adequate medication therapy. Therefore, failure
of adequate trials of at least two SSRIs or one
SSRI and a clomipramine trial and a failure of
adequately delivered CBT would constitute treat-
ment resistance. Children should have a mini-
mum of 10 weeks of each SSRI or clomipramine
at maximum recommended or maximum toler-
ated doses, with no change in dose for the
preceding 3 weeks. CBT nonresponders of ade-
quate CBT would include a child who has not
shown any improvement after 8 to 10 total ses-
sions (or six to eight sessions of E/RP) or has
substantial residual OC psychopathology after
completing standard CBT, as detailed earlier. To
summarize, the failure of at least two monothera-
pies and CBT is required before labeling a child
as treatment resistant.
Most children, however, are not nonre-
sponders, but rather partial responders. To meet
the definition of partial response, children must
have had at least 3 weeks of stable and persistent
moderate (or worse) OCD symptoms at an SSRI
dose equal to the maximal dose, or shown a flat
dose-response curve for one-dose increment
above the minimum expected starting dose, or
experienced adverse effects as a result of dosage
increase. Before rotating SSRI medications or
implementing any of the augmentation strategies
listed below, clinicians should ask themselves the
following questions: Has the child received an
adequate trial at or above the minimum starting
dose? Has the child reached the maximum dose?
Has the child been unable to tolerate a dose
above his or her current dose? Has the child been
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the child had at least 10 weeks of treatment?
Hospitalization is infrequently indicated for
OCD alone. Some children, however, require
inpatient care for comorbid conditions such as
severe mood instability or suicidal ideation. Typi-
cal inpatient psychiatric units and staff are not well
equipped to deal with youth with OCD, whose
avoidance or rituals may be misconstrued as oppo-
sitional behavior, leading to unhelpful behavioral
interventions. Few highly specialized inpatient
units exist to treat children with treatment-resistant
OCD, where the milieu and highly trained staff
provide an opportunity for intensive CBT.
Medication Augmentation Strategies. Adding
clomipramine to an SSRI may be helpful. The
rationale is to combine the serotonergic effects
of each while minimizing adverse events
across different drug classes. Fluvoxamine is
the SSRI with the most synergistic effect when
added to clomipramine, because of its ability to
inhibit the conversion of clomipramine to
desmethylclomipramine and increase the ratio in
favor of the serotonergic parent compound. Even
low-dose augmentation (25–75 mg/day) may be
useful, but care must be taken when combining
clomipramine with fluvoxamine and with CYP-450
2D6 inhibitors such as fluoxetine or paroxetine
owing to potentially toxic increases in serum clo-
mipramine levels, which must be monitored in
addition to EKG indices. Other approaches for
treatment resistance in pediatric OCD that are not
supported by randomized controlled evidence but
derive from expert opinion include the use of
venlafaxine and duloxetine, which possess similar
combined monoamine uptake inhibition properties
to clomipramine but with fewer potential cardio-
vascular adverse effects.
Clonazepam has also been used in combina-
tion with SSRIs in several small open trials but
should be used with caution in younger
children.62[ut] By far the most common drug
augmentation strategies have employed (atyp-
ical) neuroleptics. High-quality randomized
controlled trials using atypicals have been per-
formed in adults with OCD and are summarized
in a comprehensive meta-analysis by Bloch et
al.,63 but no controlled data exist in children and
only case reports and open trials have been
reported. However, expert consensus has sug-
gested that some children with treatment-resistant
OCD may benefit from judicious neuroleptic aug-
mentation, particularly children with tic
109www.jaacap.org
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mental disorder symptoms, and mood instabil-
ity. In the adult studies, an absolute response rate
difference of 21% was found in pooled data
(number needed to treat [NNT]  4.5),63 with
risperidone and haloperidol showing significant
advantage over placebo and an even better re-
sponse for those with a comorbid tic disorder
(NNT  2.3). Adverse events reported included
sedation (NNH  1.5–3) and weight gain (NNH
not computed). This meta-analysis also sug-
gested that at least 12 weeks of SSRI treatment
was required before atypical augmentation was
effective. Clinical experience indicates a mini-
mum of two different adequate SSRI trials or an
SSRI and clomipramine before atypical augmen-
tation. To repeat, no controlled data exist for the
use of atypical antipsychotics in children with
OCD. In view of the great responsibility involved
in prescribing atypical antipsychotic agents to
minors, diligence is required in assessing efficacy
and accurate safety data by practicing clinicians.
Because there is a lack of a well-defined “stan-
dard of care,” the dictum non nocere (“do no
harm”) is especially relevant. At a minimum,
regular weight and adverse event monitoring
should occur with baseline and follow-up assays
of fasting lipid profile and serum glucose.
Novel augmentation trials also have been re-
ported for stimulants, gabapentin, sumatriptan,
pindolol, inositol, opiates, St. John’s wort, and,
more recently, N-acetyl cysteine and the glutamate
antagonists memantine and riluzole, but none of
these meet minimal standards that permit recom-
mendation for their routine use. Putative PANDAS
cases of OCD have also attracted novel and exper-
imental treatment interventions. Antibiotic prophy-
laxis with penicillin failed to prevent streptococcal
infections in one study but was effective in a
subsequent study, with decreases in infections and
OCD symptoms in the year of prophylaxis com-
pared with the previous baseline year.65[rct] Extant
data are insufficient to meet minimal standards to
recommend routine antibiotic prophylaxis for chil-
dren with OCD, even when PANDAS is suspected
as an etiology. Instead, standard treatments for
OCD and streptococcal infections are recom-
mended. Therapeutic plasma exchange and intra-
venous immunoglobulin remain experimental in-
terventions with substantial risk and potential
morbidity. D-cycloserine augmentation of CBT re-
mains unproved in children, but a meta-analysis in
adults suggests efficacy.66 O
JOURN
110 www.jaacap.orgRecommendation 11. Empirically validated
medication and psychosocial treatments for co-
morbid disorders should be considered. [CG]
Because CBT interventions for OCD are focused
and time limited, additional CBT protocols that
have been empirically validated for the treatment
of disorders that are frequently comorbid with
OCD, such as oppositional-defiant disorder and
major depressive disorder, or family-based therapy
for comorbid eating disorder symptoms may be
incorporated into the treatment of the child to
enhance outcome. Insight-oriented psychotherapy,
whether delivered individually or in the family
setting, has not been shown effective in remitting
OCD symptoms in children and adolescents. Some
children who have experienced decreased function
in some important domain of life, for example, in
school grades or an ability to maintain friendships
or a loss of self-esteem or marked conflict at home
that has disrupted primary relationships as a result
of their OCD symptoms, may well benefit from
supportive psychotherapy. Family therapy for con-
flict or dysfunction that impedes treatments aimed
at the primary symptoms of OCD or for high
parental levels of accommodation to the child’s
rituals and demands may lead to better outcomes.
Pharmacotherapy for common comorbid dis-
orders is frequently needed. Almost no system-
atic data are available to guide clinicians in the
management of complex cases. When present,
ADHD is best addressed after the OCD has been
treated, because stimulants may exacerbate anx-
iety and obsessions in some children. Some mea-
surement of inattention can often be attributed to
OCD symptoms and may improve as a result of
treatment. Similarly, oppositional behavior may
ameliorate markedly with a decrease in anxiety.
However, the behavioral adverse effects of SSRIs,
especially in younger children, may mimic the
hyperactive impulsive symptoms of ADHD. Ato-
moxetine may be a useful medication in such
situations, as may clomipramine, whose metab-
olite exerts a secondary amine noradrenergic effect.
Although many children with chronic tic and
Tourette’s disorder require no pharmacological
treatment, anxiolytic treatment aimed at anxiety
and obsessional symptoms frequently ameliorates
tics. Standard anti-tic medications including the -
gonists clonidine and guanfacine may be com-
ined with antiobsessional medication, with blood
ressure, heart rate, and EKG surveillance. The
typical antipsychotics may be especially helpful in
CD comorbid with tics, but great care is required,
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ders is also often required. Medication for major
depressive disorder aligns with antiobsessional
treatment, but pediatric OCD that is comorbid with
bipolar disorder represents one of the greatest
treatment challenges in child psychiatry, because
SSRIs may exacerbate manic symptoms, even at
low doses. In these cases, mood stabilization is
usually required before OCD can be addressed.
PARAMETER LIMITATIONS
AACAP Practice Parameters are developed to as-
sist clinicians in psychiatric decision making. These
Parameters are not intended to define the sole
standard of care. As such, the Parameters should
not be deemed inclusive of all proper methods of
care nor exclusive of other methods of care directed
at obtaining the desired results. The ultimate judg-
ment regarding the care of a particular patientmust
be made by the clinician in light of all of the
circumstances presented by the patient and his or
her family, the diagnostic and treatment options
available, and the available resources. &
This Parameter was developed by Daniel A. Geller, M.B.B.S., John
March, M.D., and the AACAP Committee on Quality Issues (CQI):
Heather J. Walter, M.D., M.P.H., and Oscar G. Bukstein, M.D.,
M.P.H., Co-Chairs, and R. Scott Benson, M.D., Allan Chrisman,
M.D., Tiffany R. Farchione, M.D., John Hamilton, M.D., Helene
Keable, M.D., Joan Kinlan, M.D., Ulrich Schoettle, M.D., Matthew
Siegel, M.D., and Saundra Stock, M.D. AACAP liaison: Jennifer
Medicus.
The American Academy of Child and Adolescent Psychiatry (AACAP)
Practice Parameters are developed by the AACAP CQI in accordance
with American Medical Association policy. Parameter development is
an iterative process between the primary author(s), the CQI, topic
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